Future work will focus on validating the core targets and the biological processes these targets are involved in, as well as expanding FOXC1’s role to patient tumor samples that are more complex and heterogeneous compared to cell lines using single-cell omics. This evidence concerns the gene FOXC1 and neoplasm.